ALK and non-small cell lung carcinoma: The ability of silibinin to normalize the enhanced expression and augmented secretion of the EMT-driving factor TGFβ1 into the extracellular milieu might rather explain, at least in part, its ability to attenuate the TGFβ/SMAD signaling axis in ALK–TKIs-resistant NSCLC cells.